Introduction
============

Cachexia is characterized by loss of skeletal muscle mass with or without reduction of fat mass and is common in diseases such as cancer, chronic obstructive pulmonary disease and sepsis ([@B15]; [@B2]; [@B58]). Loss of skeletal muscle mass is an independent predictor of bad prognosis in cancer ([@B33]; [@B9]). In preclinical animal models, prevention of cancer-induced muscle loss without an effect on tumor growth ([@B7]; [@B61]; [@B39]) suggests possible causality between maintenance of muscle mass and improved survival in cachexia, but the underlying mechanisms are unknown.

Cellular protein homeostasis (i.e., proteostasis) is maintained through several integrated biological processes. For instance, undesirably modified or misfolded proteins are degraded by ubiquitin proteasome or autophagy lysosome pathways ([@B54]; [@B53]). Additionally, disrupted cellular homeostasis induced by, for example, robustly increased protein synthesis, aberrant redox control or unbalanced endoplasmic reticulum (ER) calcium homeostasis can lead to accumulation of misfolded proteins into the lumen of ER, a process also known as ER stress ([@B8]; [@B21]). Cells respond to ER stress in order to maintain homeostasis by activating unfolded protein response (UPR). It is a process which restores ER homeostasis by various mechanisms, such as increasing protein folding machinery, degrading misfolded proteins, suppressing protein synthesis and inducing autophagy. If ER stress is not rescued by UPR, metabolic impairments or apoptosis may occur ([@B21]).

In skeletal muscle, disrupted protein homeostasis has been observed in wasting conditions and muscular dystrophies. This has been manifested as increased ER stress and oxidative stress in muscular dystrophies ([@B50]; [@B55]; [@B25]), and there is some evidence that ER and oxidative stress are increased in some experimental cancer cachexia models as well ([@B13]; [@B18]; [@B6]). In skeletal muscle, cancer cachexia has been reported to induce ER stress and UPR in 2 experimental animal models: Lewis lung carcinoma (LLC) and cachectic Apc^min/+^ mice ([@B6]). Interestingly, UPR inhibition in cancer cachexia by chemical chaperone 4-PBA accelerated muscle wasting in LLC and Apc^min/+^ mice ([@B6]). Very recently, skeletal muscle specific ablation of PERK induced muscle wasting in healthy mice and further increased muscle wasting in LLC tumor bearing mice ([@B17]). In addition to skeletal muscle, increased ER stress in the liver has been observed in cachectic Apc^min/+^ mice ([@B36]). Upregulated and/or impaired autophagy has also been reported in cancer cachexia ([@B45]; [@B5]). It is unknown if UPR is ubiquitously induced in other wasting and cachexia models such as in C26 tumor-bearing mice.

Blocking activin receptor ligands using the soluble ligand binding domain of a type 2B activin receptor fused to the Fc domain (sACVR2B-Fc) rapidly increases muscle size in mice ([@B31]; [@B61]; [@B46]; [@B22]; [@B26]) and in humans ([@B4]). This occurs through increased protein synthesis ([@B26]; [@B38]) but possibly in some situations through decreased protein degradation ([@B61]). Increased muscle mass may not, however, always translate into better muscle function ([@B1]; [@B49]), perhaps in part due to qualitative changes in muscle ([@B1]; [@B49]; [@B25]; [@B32]). However, the effect of rapid muscle hypertrophy induced by an activin receptor ligand blockade on protein homeostasis is currently unknown. We previously reported improved survival in C26 tumor-bearing mice with sACVR2B-Fc treatment ([@B39]). Cachectic mice had decreased protein synthesis in skeletal muscle and increased protein synthesis in the liver, the latter of which was alleviated by sACVR2B-Fc treatment ([@B39]). Thus, we further investigated the effects of cancer cachexia and sACVR2B-Fc treatment on protein homeostasis in muscle and the liver.

The purpose of this study was to elucidate the effects of muscle wasting induced by cancer cachexia, and muscle hypertrophy induced by sACVR2B-Fc treatment on biological processes contributing to the protein and redox homeostasis in skeletal muscle. Furthermore, because skeletal muscle and the liver are known to crosstalk ([@B59]), we explored the effects of cancer and sACVR2B-Fc treatment on protein homeostasis in the liver as well. We hypothesized that both rapid atrophy and hypertrophy would alter several integrated processes that regulate protein homeostasis.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

The treatment of the animals was in strict accordance with the European convention for the protection of vertebrate animals used for experimental and other scientific purposes. The protocols were approved by the National Animal Experiment Board (Permit No.: ESLH-2009-08528/Ym-23 and ESAVI/10137/04.10.07/2014).

Animals and Cells
-----------------

### Single and 2-Week Administration of sACVR2B-Fc on Healthy Mice

Male, 6--7-week-old C57Bl/10SnJ mice were used as previously described ([@B26]). The mice were purchased from the Jackson Laboratory (Bar Harbor, ME, United States).

### The Cancer Cachexia Experiments

In the cancer cachexia experiments, 5--6-week-old male BALB/*c* (BALB/cAnCrl) mice (Charles River Laboratories) were used. All the mice were housed in standard conditions (temperature 22°C, light from 8:00 AM to 8:00 PM) and had free access to tap water and food pellets (R36, 4% fat, 55.7% carbohydrate, 18.5% protein, 3 kcal/g, Labfor, Stockholm, Sweden).

### Tumor Cell Culture

Complete Dulbecco's Modified Eagle's Medium (DMEM, high glucose, GlutaMAX^TM^ Supplement pyruvate, Gibco^TM^, Life Technologies) supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml) and 10% FBS was used for the maintenance of the colon 26 carcinoma cells as previously described ([@B39]).

Experimental Design
-------------------

This study consisted of three separate experiments (Figure [1](#F1){ref-type="fig"}), which are described in detail below.

![Overall study design. **(A)** Healthy mice were administered (i.p.) with a single dose of vehicle (PBS) or soluble activin receptor type 2B (sACVR) to block ACVR2B ligands. Muscles were collected either 1 or 2 days after the single sACVR or vehicle administration (*n*= 6--7 per group). **(B)** Healthy mice were administered (i.p.) with vehicle (PBS) or sACVR for 2 weeks (1--2 times per week) and muscles were collected (*n* = 6 in PBS and *n* = 11 in sACVR 2wk). **(C)** C26 cancer experiment: (1) CTRL (+PBS, *n* = 9), (2) C26 + PBS (*n* = 7), (3) C26 + sACVR/b (*n* = 7), and (4) C26 + sACVR/c (*n* = 8). Cancer groups were inoculated subcutaneously (s.c.) with C26 cells on day 11. The vehicle (PBS) and sACVR2B-Fc were administered (i.p.) every fourth day. Muscles and livers were collected 11 days after the C26 cell inoculation.](fphys-09-01917-g001){#F1}

### Acute sACVR2B-Fc Experiment in Healthy Mice

To study the acute effects of sACVR2B-Fc administration in healthy skeletal muscle, mice were divided into three groups that were euthanized 1 or 2 days after a single injection of PBS (i.p.) or sACVR2B-Fc (10 mg/kg, i.p.) as previously described ([@B26]; Figure [1A](#F1){ref-type="fig"}).

### Two-Week sACVR2B-Fc Experiment in Healthy Mice

To study the short-term effects of sACVR2B-Fc administration in healthy skeletal muscle, mice were randomly divided into mice administered (i.p., 1--2 times per week) with (1) PBS or (2) sACVR2B-Fc as previously described ([@B26]; Figure [1B](#F1){ref-type="fig"}).

### Cancer Cachexia Experiment

Mice were randomized into one of the four weight-matched groups: (1) vehicle-treated (PBS) healthy control mice (CTRL), (2) C26 tumor-bearing mice administered with a vehicle (PBS) (C26 + PBS), (3) C26 tumor-bearing mice administered with sACVR2B-Fc before the C26 tumor formation and replaced by a vehicle (PBS) after the tumor formation (C26 + sACVR/b), and (4) C26 tumor-bearing mice continuously administered with sACVR2B-Fc throughout the experiment (C26 + sACVR/c). Cancer groups were inoculated subcutaneously (s.c.) with C26 colon carcinoma cells (5 × 10^5^ cells in ∼ 120 μl PBS) into their interscapular region. The vehicle (PBS) and sACVR2B-Fc (5 mg/kg in ∼ 100 μl PBS) were administered (i.p.) every fourth day (Figure [1C](#F1){ref-type="fig"}). The weight loss from day 10 to 11 after C26 inoculation strongly predicted survival ([@B39]) and thus the end-point was chosen to be 11 days after the C26 inoculation to represent the onset of cachexia. When the symptoms of cancer started to occur, mice were strictly and carefully monitored according to the end-point guidelines of animal experiments approved by the National Animal Experiment Board. However, none of the mice fulfilled the end-point criteria before the actual end-point.

### sACVR2B-Fc Production

The production of the recombinant sACVR2B-Fc, which is similar but not totally identical with the original version generated by [@B31], has been described in detail before ([@B26]). Briefly, we fused a human IgG1 Fc domain with the ectodomain of human ACVR2B and the protein was expressed in Chinese hamster ovary cells grown in suspension culture.

Tissue Collection and Processing
--------------------------------

### Tissue Collection

In the acute and 2-week experiments the mice were euthanized by cervical dislocation and gastrocnemius muscles were weighed and subsequently flash frozen in liquid nitrogen and stored at -80°C for further analysis. In the cancer experiment mice were euthanized by cervical dislocation after heart puncture under anesthesia \[ketamine (Ketaminol^®^): ∼110--120 mg/kg + xylazine (Rompun^®^): 15--16 mg/kg\]. Gastrocnemius, tibialis anterior (TA) and liver were weighed and flash frozen in liquid nitrogen and were stored at -80°C for further analysis.

### RNA Extraction and cDNA Synthesis

In the cancer cachexia experiment, total RNA was extracted from gastrocnemius muscles with QIAzol and were purified with RNeasy Universal Plus kit (Qiagen). The quality of RNA was confirmed by spectrophotometry (NanoDrop; Thermo Fisher Scientific) and agarose gel electrophoresis. iScript^TM^ Advanced cDNA Synthesis Kit (Bio-Rad Laboratories) was used to reverse transcribe the RNA to cDNA. Both steps were conducted according to the manufacturer's guidelines.

### Protein Extraction and Content Measurement

Muscle and liver samples were homogenized in ice-cold buffer with protease and phosphatase inhibitors as previously described ([@B26]; [@B39]). The total protein content was measured using the bicinchoninic acid protein assay (Pierce Biotechnology, Rockford, IL, United States) with an automated KoneLab analyzer (Thermo Fisher Scientific, Vantaa, Finland).

Tissue Analyses
---------------

### Real-Time-qPCR

mRNA expression levels were analyzed with RT-qPCR following standard procedures using iQ SYBR Supermix (Bio-Rad Laboratories) and CFX96 real-time PCR Detection system. The mRNA levels of *Chop*/*Ddit3* (assay ID qMmuCID0020314), *Lc3b* (assay ID qMmuCED0048150), and *P62* (assay ID qMmuCID0024517) were measured with pre-designed and pre-validated primers (Bio-Rad PrimePCR^TM^ SYBR Green assays). The protocol recommended by the manufacturer was used. The spliced variant mRNA level of X-box binding protein 1 (*Xbp1s*) was analyzed using SYBR green primers: forward: TGCTGAGTCCGCAGCAGGTG and reverse: CTGATGAGGTCCCCACTGACAGA (Invitrogen, United States). The protocol for the *Xbp1s* was initiated at 95°C which was followed by 39 cycles of denaturation at 95°C for 10 s, annealing at 61°C for 30 s and extension at 68°C for 30 s. mRNA expression levels were calculated from the exponential amplification phase using the efficiency corrected ΔΔCT method. *36b4* (Forward primer: 5′-GGCCCTGCACTCTCGCTTTC-3′, Reverse primer: 5′-TGCCAGGACGCGCTTGT-3′) was used as a house-keeping reference gene because it was unaffected by the cancer and the sACVR2B-Fc treatments as previously reported (*p*\> 0.16) ([@B39]).

### Western Blot

Western blot analyses were conducted in two laboratories and therefore slightly different protocols are provided below:

*LC3B, P62, Bcl-2, Beclin-1, p-ULK1^ser757^, ULK1, PERK, p-eIF2α^ser51^, total eIF2α, IRE1α, p-JNK54, JNK54, PDI, ATF4, Cleaved Caspase 3 and 12* as well as *HSP25, GRP78, and HSP47* were analyzed only from the cancer experiment by a protocol previously described in more detail ([@B26]; [@B20]). In short, muscle and liver homogenates mixed with Laemmli sample buffer + β-mercaptoethanol were heated at 95°C to denature proteins. Proteins were separated with SDS--PAGE and transferred to a PVDF membrane, blocked (5% fat-free milk in TBS-T) and incubated overnight at 4°C with primary antibodies. The membrane was then washed and incubated with secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, United States) for 1 h followed by washing. Proteins were visualized by enhanced chemiluminescence (SuperSignal West Femto maximum sensitivity substrate, Pierce Biotechnology, Rockford, IL, United States) using a ChemiDoc XRS device and quantified with Quantity One software (version 4.6.3. Bio-Rad Laboratories, Hercules, CA, United States). The uniformity of the protein loading was confirmed by staining the membrane with Ponceau S and by re-probing the membrane with an antibody against GAPDH (Abcam, Cambridge, United Kingdom). The results were normalized to the mean of Ponceau S (strong band at ∼42 kDa) and GAPDH value.

*HSP60, HSP70, HSP90 TRX, and TxNIP* as well as *GRP78, HSP25, and HSP47* were analyzed from the acute experiments by a protocol as described previously ([@B3]; [@B29]). Briefly, protein extracts (20 μg protein per well) with molecular weight markers were electrophoresed on SDS/PAGE and transferred to a nitrocellulose membrane (Millipore, Bedford, MA, United States). The uniformity of the protein loading was confirmed by staining the membrane with Ponceau S and by re-probing the membrane with an antibody against Actin (Sigma, A-2066). Membranes were blocked with 5% fat-free milk solution at 37°C for 1 h and treated with monoclonal or polyclonal antibodies overnight at 4°C (StressGen, VIC, Canada; IMCO, Stockholm, Sweden; MBL International, Woburn, MA, United States; Sigma, St. Louis, MO, United States). Immunoblots were visualized by Odyssey (LI-COR Biosciences Inc., Lincoln, NB, United States) and quantified by Odyssey Software.

### Antibodies

Antibodies for IRE1α (\#3294), PDI (\#3501), PERK (\#3192), eIF2α (\#5324) and its phosphorylated form at ser51 (\#3398, p-eIF2α^ser51^) GRP78 (used in the cancer experiment, \#3177), P62 (\#5114), Bcl-2 (\#3498), p-ULK1^ser757^ (\#14202), ULK1 (\#8054), p-JNK^Thr183/Tyr185^ (\#4668), JNK (\#9252), ATF4 (\#11815), Beclin-1 (\#3495), caspase 12 (\#2202), and cleaved caspase 3 (\#9661) were purchased from Cell Signaling Technology. GAPDH (ab9485) antibody was purchased from Abcam (Cambridge, United Kingdom). LC3I and LC3II were measured by antibody (L7543) that was purchased from Sigma-Aldrich (St. Louis, MO, United States). Monoclonal primary antibodies were used for the detection of heat shock protein 70 (HSP70, StressGen, SPA-810), heat shock protein 60 (HSP60, StressGen, SPA-806), heat shock protein 90 (HSP90, StressGen, SPA-835), heat shock protein 47 (HSP47, StressGen, SPA-470) and thioredoxin interacting protein (TXNIP and MBL). Polyclonal primary antibodies were used to detect thioredoxin (TRX, IMCO, and ATRX-06), actin (Sigma, A-2066), heat shock protein 25 (HSP25, StressGen, and SPA-801), glucose-regulated protein 78 (GRP78, StressGen, SPA-826, used in the acute experiments). Horseradish peroxidase conjugated IgG secondary antibodies were used (Jackson ImmunoResearch Laboratories, PA, United States and StressGen and Zymed, San Francisco, CA, United States).

### Analysis of Protein Carbonyls

In the acute and 2 weeks experiments protein carbonyls were analyzed by western blot technique after derivatization with 2,4-dinitrophenyl hydrazine immediately before the electrophoresis, as previously described ([@B25]). In the C26 cancer experiment, the principle of the measurement was the same as with acute and 2 weeks experiment. However, the measurement was carried out with a commercial OxyBlot Protein Oxidation Detection kit (Merck Millipore, S1750) according to manufacturer's instructions as previously described ([@B20]).

### Glutathione Assays

After gastrocnemius muscle homogenization, total glutathione (TGSH) was measured spectrophotometrically by an oxidized glutathione (GSSG) reductase recycling method as described earlier ([@B29]; [@B25]). The rate of change in absorbance at 412 nm was monitored with a double-beam spectrophotometer at room temperature and tissue concentrations were estimated by linear regressions from the standard curve.

Statistical Methods
-------------------

The main effect was analyzed by one-way analysis of variance (ANOVA) or the Kruskal-Wallis test, followed by Holm-Bonferroni corrected LSD or Mann-Whitney U *post hoc* tests depending on the distribution of the data (Shapiro-Wilk). The effect of 2-week sACVR2B-Fc (sACV 2wk vs. PBS 2wk) administration was examined with Student's *t* test or Mann Whitney U if data were not normally distributed. The C26 cancer effect (CTRL vs. C26 + PBS and CTRL vs. C26 groups pooled) was analyzed with Student's *t* test or the Mann-Whitney *U*-test when data were not normally distributed. Correlations were analyzed using Pearson's product-moment coefficient.

PASW statistics version 24.0 was used for statistical analyses (SPSS, Inc., Chicago, IL, United States). The level of significance was set at *P* ≤ 0.05. Data are expressed as means ± SE.

Results
=======

Background Results
------------------

This is a follow-up study on our two previous studies. In brief, in [@B39] we showed that C26 tumor implantation resulted in muscle and fat wasting and increased hepatic protein synthesis as well as acute phase response, a cytokine-induced early defense mechanism ([@B10]). Treating mice with sACVR2B-Fc increased muscle mass and protein synthesis in healthy mice ([@B26]) and prevented muscle loss and prolonged survival in tumor-bearing mice without affecting the tumor size when sACVR2B-Fc was administered continuously before and after the C26 cell inoculation ([@B39]).

Two-Week sACVR2B-Fc Administration Induces Unfolded Protein Response
--------------------------------------------------------------------

The protein content of UPR indicators and ER-resident chaperones were unchanged 1 and 2 days after the single sACVR2B-Fc administration (Figures [2A](#F2){ref-type="fig"}--[G](#F2){ref-type="fig"}) when muscle protein synthesis was greatly induced ([@B27]). Later, after 2 weeks of sACVR2B-Fc administration, the phosphorylation of eIF2α^Ser51^ (*p* \< 0.05) was increased without changes in total eIF2α (Figures [2A,B](#F2){ref-type="fig"}). In addition, ER resident chaperones GRP78 (*p* \< 0.05) and HSP47 (*p* \< 0.01) were increased (Figures [2C,D](#F2){ref-type="fig"}), suggesting partial induction of UPR by 2-week sACVR2B-Fc administration, while other UPR indicators were unchanged (PERK, PDI, and IRE1α) (Figures [2E](#F2){ref-type="fig"}--[G](#F2){ref-type="fig"}).

![Unfolded protein response (UPR) markers in healthy skeletal muscle in mice that were administered with soluble activin receptor type 2B (sACVR) or vehicle (PBS). Muscles were collected 1 or 2 days after a single sACVR administration or after 2 weeks of administration. **(A)** p-eIF2α^ser51^, **(B)** total eIF2α protein, **(C)** GRP78 protein, **(D)** HSP47 protein, **(E)** PDI protein, **(F)** PERK protein, **(G)** IRE1α protein; *n* = 6--7 in all groups except *n* = 9--11 in sACVR 2 Wk group. The symbol ^∗^ depicts statistical significance *p* \< 0.05 whereas the symbol ^∗∗^ depicts statistical significance *p* \< 0.01. Data is expressed as means ± SE. Representative blots were cropped from the original blot images (Supplementary Figures [6--8](#SM1){ref-type="supplementary-material"}). Representative blots with same IDs and analyzed in the same run are aligned on top of each other and share the same representative control blot (GAPDH or actin).](fphys-09-01917-g002){#F2}

Protein Carbonylation and the Reduced Form of Glutathione Are Increased by sACVR2B-Fc Administration
----------------------------------------------------------------------------------------------------

As a marker of oxidative damage, protein carbonyls were increased 1 and 2 days after the sACVR2B-Fc administration in skeletal muscle (Day 1: *p* \< 0.05, Day 2: *p* = 0.06, Figure [3A](#F3){ref-type="fig"}) and remained increased after 2 weeks of sACVR2B-Fc administration (*p* \< 0.05) (Figure [3A](#F3){ref-type="fig"}). Possibly as a delayed response to increased oxidative stress, there was an increase in reduced glutathione (*p* \< 0.05, Figure [3B](#F3){ref-type="fig"}) and a trend for increased TRX protein content (*p* = 0.10, Figure [3E](#F3){ref-type="fig"}) after 2 weeks of sACVR2B-Fc administration without changes in the protein content of TxNIP (Figure [3F](#F3){ref-type="fig"}). Oxidized glutathione (GSSG) concentration (Figure [3C](#F3){ref-type="fig"}) and the ratio of oxidized and reduced glutathione (GSSG/GSH) (Figure [3D](#F3){ref-type="fig"}) were unchanged by the sACVR2B-Fc administration in all the time-points. Of the heat shock response indicators, 2-week sACVR2B-Fc administration increased only the protein content of small heat shock protein 25 (HSP25) at 2 weeks (*p* \< 0.001, Figure [4A](#F4){ref-type="fig"}) without changes in larger HSPs 60, 70, and 90 at any time-point (Figures [4B](#F4){ref-type="fig"}--[D](#F4){ref-type="fig"}).

![Redox-balance markers in healthy skeletal muscle in mice that were administered with soluble activin receptor type 2B (sACVR) or vehicle (PBS). Muscles were collected 1 or 2 days after a single sACVR administration or after 2 weeks of administration. **(A)** Protein carbonyls, **(B)** reduced glutathione (GSH), **(C)** oxidized glutathione (GSSG), **(D)** ratio of oxidized glutathione to reduced glutathione (GSSG/GSH), **(E)** TRX protein, **(F)** TxNIP protein; *n* = 5--6 in all groups except *n* = 8--11 in sACVR 2 Wk group. The symbol ^∗^ depicts statistical significance *p* \< 0.05. Data is expressed as means ± SE. Representative blots were cropped from the original blot images (Supplementary Figure [7](#SM1){ref-type="supplementary-material"}). Representative blots of TRX and TxNIP share the same IDs and were analyzed in the same run and are thus aligned on top of each other and share the same representative control blot (actin). Protein carbonyls were normalized to total protein loading.](fphys-09-01917-g003){#F3}

![Heat shock protein (HSP) response markers in healthy skeletal muscle in mice that were administered with soluble activin receptor type 2B (sACVR) or vehicle (PBS). Muscles were collected 1 or 2 days after a single sACVR administration or after 2 weeks of administration. **(A)** HSP25, **(B)** HSP60, **(C)** HSP70, and **(D)** HSP90; *n* = 6--7 in all groups except *n* = 10--11 in sACVR 2 Wk group. The symbol ^∗∗∗^ depicts statistical significance *p* \< 0.001. Data is expressed as means ± SE. Representative blots were cropped from the original blot images (Supplementary Figure [8](#SM1){ref-type="supplementary-material"}). Representative blots with same IDs and analyzed in the same run are aligned on top of each other and share the same representative control blot (actin).](fphys-09-01917-g004){#F4}

Decreased Glutathione Levels in C26 Tumor-Bearing Mice Are Restored by Continued sACVR2B-Fc Administration
----------------------------------------------------------------------------------------------------------

Next, we investigated the effects of the C26 tumor that induced cachexia and sACVR2B-Fc administration that alleviated cachexia. As a marker of skeletal muscle redox balance, the reduced form of glutathione was decreased in PBS-treated tumor-bearing mice compared with healthy controls (*p* \< 0.001, Figure [5A](#F5){ref-type="fig"}). This was accompanied by increased ratio of oxidized glutathione and reduced glutathione (GSSG/GSH), suggesting increased oxidative stress (*p*\< 0.001, Figure [5B](#F5){ref-type="fig"}). Interestingly, sACVR/c administration prevented the decrease in reduced glutathione levels (*p* \< 0.05), thus decreasing the GSSG/GSH ratio (pooled sACVR effect, *p* \< 0.05) (Figure [5B](#F5){ref-type="fig"}). Oxidized glutathione concentration (GSSG) (Figure [5C](#F5){ref-type="fig"}) and a marker of oxidative damage/stress, protein carbonyl content were unaltered by cancer and sACVR2B-Fc treatment (Figure [5D](#F5){ref-type="fig"}).

![Redox balance markers in skeletal muscle of C26 tumor-bearing mice. **(A)** Reduced glutathione (GSH), **(B)** ratio of oxidized to reduced glutathione (GSSG/GSH), **(C)** oxidized glutathione (GSSG), and **(D)** protein carbonyls. CTRL, vehicle-treated (PBS) healthy control mice, *n* = 7--9. C26 + PBS = C26 tumor-bearing mice administered with a vehicle (PBS), *n* = 7. C26 + sACVR/b = C26 tumor-bearing mice administered with sACVR before the tumor formation and replaced by a vehicle (PBS) after the tumor formation, *n* = 7. C26 + sACVR/c = C26 tumor-bearing mice continuously administered with sACVR throughout the experiment, *n* = 8. The symbol ^∗^ depicts statistical significance *p* \< 0.05 whereas the symbol ^∗∗∗^ depicts statistical significance *p* \< 0.001. For the pooled effect sACVR administered groups were pooled. Data is expressed as means ± SE. Protein carbonyls were normalized to Ponceau S staining (strongest band at ∼42 kDa). Representative protein carbonyl blot was cropped from the original blot image (Supplementary Figure [10](#SM1){ref-type="supplementary-material"}).](fphys-09-01917-g005){#F5}

Cancer Cachexia Is Associated With Decreased HSP47, p-eIF2α, and p-JNK54 of the UPR Indicators in Muscle
--------------------------------------------------------------------------------------------------------

Of the UPR markers, C26 cancer decreased the phosphorylation of eIF2α at Ser^51^ and the phosphorylation of JNK54 at Thr^183^/Tyr^185^, as well as decreased the levels of HSP47 protein in skeletal muscle (*p*\< 0.05, Figure [6A](#F6){ref-type="fig"}). In addition, the mRNA level of the pro-apoptotic indicator *Chop* tended to be decreased when tumor-bearing groups were pooled (*p* = 0.06, Figure [6B](#F6){ref-type="fig"}). Other UPR indicators remained unaltered by C26 cancer (Figures [6A,C](#F6){ref-type="fig"}). The continued sACVR2B treatment (sACVR/c) increased GRP78 protein (*p* \< 0.05) compared to PBS-administered mice and tended to increase p-eIF2α^Ser51^ (*p* = 0.18), HSP47 (*p* = 0.11), and p-JNK54 (*p* = 0.14) to healthy control levels (Figure [6A](#F6){ref-type="fig"}). A mitochondrial UPR marker HSP10 and HSP25 were unaltered by C26 cancer (Figures [6D,E](#F6){ref-type="fig"}). However, when sACVR2B treated groups were pooled, HSP25 protein was increased compared to PBS-treated C26 tumor-bearing mice (*p* \< 0.05, Figure [6E](#F6){ref-type="fig"}).

![Unfolded protein response (UPR) and heat shock protein (HSP) response markers in skeletal muscle of C26 tumor-bearing mice. **(A)** Protein content of UPR markers (PERK, p-eIF2α^ser51^, eIF2α, GRP78, HSP47, IRE1α, p-JNK54, JNK54, and PDI), **(B)** mRNA level of *Chop*, and **(C)** of spliced *Xbp1 (Xbp1s)*. **(D)** Protein content of HSP10 and **(E)** HSP25. CTRL, vehicle-treated (PBS) healthy control mice, *n* = 7. C26 + PBS = C26 tumor-bearing mice administered with a vehicle (PBS), *n* = 7. C26 + sACVR/b = C26 tumor-bearing mice administered with sACVR before the tumor formation and replaced by a vehicle (PBS) after the tumor formation, *n* = 7. C26 + sACVR/c = C26 tumor-bearing mice continuously administered with sACVR throughout the experiment, *n* = 8. The symbol ^∗^ depicts statistical significance *p* \< 0.05. For the C26 effect all the tumor-bearing groups were pooled. For the sACVR pooled effect both of the sACVR groups were pooled. Data is expressed as means ± SE. Representative blots were cropped from the original blot images (Supplementary Figures [9](#SM1){ref-type="supplementary-material"}, [10](#SM1){ref-type="supplementary-material"}). Representative blots with same IDs and analyzed in the same run are aligned on top of each other and share the same representative control blot (GAPDH).](fphys-09-01917-g006){#F6}

Selective Hepatic UPR Is Induced in Tumor-Bearing Mice
------------------------------------------------------

In the liver, the UPR indicators PERK (*p* \< 0.05), p-eIF2α^Ser51^ (*p* \< 0.01) (no change in total eIF2α) and GRP78 (*p* \< 0.001) were increased by C26 cancer (Figures [7A](#F7){ref-type="fig"}--[D](#F7){ref-type="fig"}). However, ATF4 protein content was greatly decreased (*p*\< 0.01, Figure [7E](#F7){ref-type="fig"}) and there was a trend for decrease in IRE1α (*p* = 0.053, Figure [7F](#F7){ref-type="fig"}). Phosphorylation of JNK was unaltered by cancer (Figure [7G](#F7){ref-type="fig"}) but total JNK was increased in tumor-bearing mice when groups were pooled (*p* \< 0.05, Figure [7H](#F7){ref-type="fig"}). sACVR2B-Fc administration had no significant effect on any of the variables. Pro caspase 12 was decreased (*p* \< 0.05) by C26 cancer but its cleaved form was unchanged (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). In addition, cleaved caspase 3 (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}) was unchanged, suggesting that apoptosis was not activated at this time point.

![Unfolded protein response (UPR) markers in the liver of C26 tumor-bearing mice. **(A)** PERK protein, **(B)** p-eIF2α^ser51^, **(C)** eIF2α, **(D)** GRP78 protein, **(E)** ATF4 protein, **(F)** IRE1α protein, **(G)** mean of p-JNK46 and p-JNK54, and **(H)** mean of total JNK46 and JNK54 protein. CTRL, vehicle-treated (PBS) healthy control mice, *n* = 9. C26 + PBS = C26 tumor-bearing mice administered with a vehicle (PBS), *n* = 7. C26 + sACVR/b = C26 tumor-bearing mice administered with sACVR before the tumor formation and replaced by a vehicle (PBS) after the tumor formation, *n* = 7. C26 + sACVR/c = C26 tumor-bearing mice continuously administered with sACVR throughout the experiment, *n* = 8. The symbol ^∗^ depicts statistical significance *p* \< 0.05, the symbol ^∗∗^ depicts statistical significance *p* \< 0.01 and the symbol ^∗∗∗^ depicts statistical significance *p* \< 0.001. For the C26 effect, tumor-bearing groups were pooled. Data is expressed as means ± SE. Representative blots were cropped from the original blot images (Supplementary Figures [11](#SM1){ref-type="supplementary-material"}, [12](#SM1){ref-type="supplementary-material"}). Representative blots with same IDs and analyzed in the same run are aligned on top of each other and share the same representative control blot (GAPDH).](fphys-09-01917-g007){#F7}

Autophagy-Lysosome Pathway Is Induced in Skeletal Muscle and Liver of Tumor-Bearing Mice
----------------------------------------------------------------------------------------

In skeletal muscle, lipidated LC3 (LC3II) (*p* = 0.051) and the ratio of LC3II to LC3I (*p* \< 0.05) which can be used as a marker of autophagosome content, were both increased by the C26 cancer (Figure [8A](#F8){ref-type="fig"}). In addition, Beclin-1, involved in autophagy induction was increased by C26 cancer (*p* \< 0.01, Figure [8A](#F8){ref-type="fig"}). Moreover, the protein content of P62, which acts as an adaptor protein sequestering cellular compartments that are to be degraded by autophagy--lysosome pathway, was also increased by C26 cancer (*p* \< 0.01, Figure [8A](#F8){ref-type="fig"}). *Lc3b* mRNA (*p* \< 0.05, Figure [8C](#F8){ref-type="fig"}) was increased by cancer whereas the protein content of LC3I, p-ULK1^Ser757^ as well as total ULK1 and Bcl-2 and *p62* mRNA were unaltered (Figures [8A,B](#F8){ref-type="fig"}).

![Autophagy markers in skeletal muscle and the liver of C26 tumor-bearing mice. **(A)** Protein content of autophagy markers in skeletal muscle (LC3II, LC3I, LC3II/LC3I, P62, Beclin-1, p-ULK1^ser757^, total ULK1, and Bcl-2). The mRNA level of **(B)** *P62* and **(C)** *Lc3b* in skeletal muscle. **(D)** Protein content of autophagy markers in the liver (LC3II, LC3I, LC3II/LC3I, P62, p-ULK1^ser757^, and Beclin-1). CTRL, vehicle-treated (PBS) healthy control mice, *n* = 7--9. C26 + PBS = C26 tumor-bearing mice administered with a vehicle (PBS), *n* = 7. C26 + sACVR/b = C26 tumor-bearing mice administered with sACVR before the tumor formation and replaced by a vehicle (PBS) after the tumor formation, *n* = 7. C26 + sACVR/c = C26 tumor-bearing mice continuously administered with sACVR throughout the experiment, *n* = 8. The symbol ^∗^ depicts statistical significance *p* \< 0.05 and the symbol ^∗∗^ depicts statistical significance *p* \< 0.01. For the C26 effect, tumor-bearing groups were pooled. Data is expressed as means ± SE. Representative blots were cropped from the original blot images (Supplementary Figures [9, 11](#SM1){ref-type="supplementary-material"}, [12](#SM1){ref-type="supplementary-material"}). Representative blots with same IDs and analyzed in the same run are aligned on top of each other and share the same representative control blot (GAPDH).](fphys-09-01917-g008){#F8}

LC3II (*p* \< 0.05), LC3II/I (*p* \< 0.01), and Beclin-1 (*p* \< 0.05) increased in the liver by the C26 cancer without changes in p-ULK1^Ser757^ and P62 protein (Figure [8D](#F8){ref-type="fig"}). Contrary to skeletal muscle, LC3I (*p* \< 0.05) increased in the liver by C26 cancer. The discontinued administration of sACVR2B-Fc further increased LC3II/I in skeletal muscle compared to other tumor-bearing groups (*p* \< 0.01, Figure [8A](#F8){ref-type="fig"}). Otherwise there were no systematic effects of sACVR2B-Fc administration on the autophagy indicators in skeletal muscle or in the liver (Figures [8A](#F8){ref-type="fig"}--[D](#F8){ref-type="fig"}).

Discussion
==========

We demonstrated that muscle hypertrophy induced by blocking ACVR2B ligands increased markers of unfolded protein response (UPR) and the reduced form of glutathione. On the other hand, experimental C26 cancer cachexia was accompanied by decreased levels of reduced glutathione, indicating a decline in antioxidant defense capacity in skeletal muscle. Interestingly, blocking ACVR2B ligands restored this decline. Moreover, we showed that selective UPR was induced in the liver, but not in skeletal muscle during the onset of rapid weight loss in experimental cancer.

We ([@B39]) and others ([@B7]; [@B61]) have previously shown that the prevention of cancer cachexia without any effect on tumor growth improves survival in experimental mouse models. This result suggests a possible causality between the prevention of muscle loss and improved survival in cachexia, but its underlying mechanisms are unknown. More specifically, we showed that a soluble growth factor receptor, namely sACVR2B-Fc, improved survival in C26 cancer cachexia only when the treatment continued after the tumor formation, whereas a discontinued prophylactic treatment had no positive survival effects ([@B39]). In the present study, we further investigated the tumor-bearing mice and elucidated the role of biological processes regulating protein homeostasis. We observed altered redox balance, which shifted toward increased oxidative stress manifested by decreased levels of reduced glutathione (GSH) resulting in an increased ratio of oxidized to reduced glutathione (GSSG/GSH) in the skeletal muscle of tumor-bearing mice. The result is consistent with previous studies in which hallmarks of altered redox state were manifested by decreased levels of GSH ([@B18]) and a depletion of antioxidant peptides (glutathione, anserine, and carnosine), accompanied by a shift of the ratio of mannitol and mannose toward the oxidized form ([@B13]) in the skeletal muscle of tumor-bearing mice. Interestingly, together with improving survival ([@B39]), only the continued blocking of ACVR2B ligands restored glutathione levels in cachectic skeletal muscle in line with the levels in the healthy mice. Moreover, blocking ACVR2B ligands increased the reduced form of glutathione in healthy mice as well, suggesting that the effect is not limited to cachectic muscle only. This supports the earlier study in which the absence of normal myostatin signaling *per se* increased GSH concentration ([@B47]). We also observed that muscle GSH concentration correlated positively with adipose tissue mass, skeletal muscle mass and change in body mass (last 2 days of the experiment) as well as negatively with tumor mass, suggesting that skeletal muscle GSH depletion is associated with the severity of the cachexia (Supplementary Figures [2A--D](#SM1){ref-type="supplementary-material"}). Indeed, in a previous study, administration of glycine, which is a precursor for glutathione, improved muscle function and inhibited muscle wasting in C26 cachexia ([@B18]), suggesting that the reduced GSH may have an impact on the cachexia progression and restoring the redox balance may be beneficial.

The increase in GSH may also be a compensatory mechanism for increased oxidative damage/stress after a single or repeated sACVR administration. Unlike in healthy mice, protein carbonyls were, however, unchanged in tumor-bearing mice with or without blocking ACVR2B ligands. The accumulation of oxidatively damaged proteins is also known to induce proteasome activity intended to achieve their removal ([@B48]). Therefore, no difference in oxidatively modified protein levels may be explained by their increased removal. To support this assumption we observed increased markers of protein degradation ([@B39]) and in the current study increased markers of autophagy. Thus, a possible increase of oxidative protein modification cannot be discarded in tumor-bearing mice. Heat shock proteins are known to be induced, for example, by oxidative and metabolic stress ([@B37]). We did not observe induction of the expression HSPs 60, 70, and 90 in healthy skeletal muscle, which does not support the assumption that sACVR2B-Fc administration increases cellular and especially oxidative stress. However, the expression of HSP25, which is also known to protect cells from oxidative stress ([@B14]) was also upregulated in healthy and cachectic sACVR administered mice, the effect being more profound in healthy muscle. This result is in line with previous literature in which skeletal muscle hypertrophy was observed ([@B23]; [@B16]; [@B24]), suggesting that induction of HSP25 regulates muscle homeostasis during rapid muscle hypertrophy. We analyzed only HSP content to assess heat shock response and not their subcellular localization, which is a key feature of their function ([@B43], [@B42]). Future studies are warranted to investigate the effect of blocking ACVR2B ligands on oxidative stress and redox regulation as well as HSP localization in more detail.

To further investigate muscle protein homeostasis, we analyzed several indicators of unfolded protein response (UPR), a process that is also known to be induced by ER stress and oxidative stress ([@B8]). We observed that ER stress and UPR are not induced at the onset of C26 induced cachexia and, if anything, UPR may instead be downregulated. These observations are in line with decreased p-eIF2α in C26 tumor-bearing mice ([@B44]). However, they are contrary to a previous study in which UPR in skeletal muscle was upregulated in two other commonly used experimental animal models of cancer cachexia: LLC and Apc^min/+^ mice. Interestingly, UPR seems to protect muscles from further wasting in these experimental cancer models ([@B6]; [@B17]). The decreased UPR indicators were associated with the severity of cachexia because the downregulated UPR indicators (p-eIF2α, HSP47 and p-JNK) correlated positively with the change in body mass between the last 2 days of the experiment and negatively with the tumor mass (Supplementary Figures [3A--F](#SM1){ref-type="supplementary-material"}). Alternatively, the decreased levels of UPR indicators in skeletal muscle that we observed in tumor-bearing mice could possibly be explained by decreased overall protein synthesis ([@B39]), which would reduce the demand of the folding of the nascent newly synthesized proteins. To support this, p-eIF2α, HSP47, and p-JNK correlated positively with muscle protein synthesis (Supplementary Figures [4A--C](#SM1){ref-type="supplementary-material"}). Another possible mechanism downregulating these indicators may be a decrease in physical activity that we previously reported ([@B39]) because HSP47 has been shown to decline during muscle unloading ([@B41]) and phosphorylation of JNK has been shown to be inducible by resistance exercise ([@B20]) and mechanical strain ([@B34]).

Interestingly, many of the downregulated UPR markers in cancer were or tended to be increased in mice that received continued sACVR2B-Fc treatment, compared with other tumor-bearing mice. In healthy mice, 2-week sACVR2B-Fc administration increased the same UPR markers (GRP78, HSP47, and p-eIF2α) that also tended to be upregulated in sACVR2B-Fc administered C26 tumor-bearing mice. This suggests that these UPR indicators are upregulated more ubiquitously by sACVR2B-Fc administration. However, UPR indicators were not induced acutely 1 or 2 days after a single administration of sACVR2B-Fc, even though the protein synthesis was greatly induced, as we previously reported ([@B26]). This is contrary to another stimulus, increasing protein synthesis, resistance exercise (RE), which has been shown to induce UPR 1 and 2 days after the RE bout ([@B40]; [@B20]). Thus, it is suggested that UPR activation following sACVR2B-Fc ligand blocking is delayed compared with a RE bout. Previously, activation of UPR has been shown to inhibit mTORC1 signaling ([@B12], [@B11]) and was suggested to act as a molecular break, suppressing protein synthesis during rapid muscle growth ([@B19]). Indeed, based on growth curves, the rate of muscle growth seemed to reach a plateau after 10 days during the sACVR2B-Fc administration ([@B26]), which might be attributed to the induction of UPR and consequently blunted muscle growth.

We previously reported increased hepatic protein synthesis and induction of acute phase response (APR), suggesting altered protein homeostasis in the liver of tumor-bearing mice ([@B39]). Thus, we also analyzed UPR indicators in the liver of the tumor-bearing mice. In contrast to skeletal muscle, PERK, p-eIF2α, and GRP78 were increased by C26, whereas ATF4 protein content was strongly decreased. These results suggest that specific branches of UPR are activated in the liver of the tumor-bearing mice while some indicators may respond with a strong decrease. In a previous study, specific UPR markers have been associated with the severity of the cachexia: the pro-apoptotic indicators were especially associated with the progression of cachexia ([@B36]). To analyze the maladaptive UPR branch that drives apoptosis, we analyzed the content of the ER stress-specific apoptosis marker caspase 12 ([@B56]) from the livers of tumor-bearing mice. Interestingly, the content of the cleaved, active caspase 12 was unchanged, but the uncleaved pro caspase 12 was decreased in the liver of tumor-bearing mice. In addition, another ER-stress-associated pro-apoptotic indicator, JNK phosphorylation ([@B57]; [@B56]) and the apoptosis marker cleaved caspase 3 were unchanged. This suggests that ER-stress-driven apoptosis was not induced in the liver of tumor-bearing mice. Nevertheless, the hepatic UPR markers GRP78 and ATF4 correlated positively with the change in body mass (the last 2 days of the experiment) (Supplementary Figures [5A,B](#SM1){ref-type="supplementary-material"}) and ATF4 correlated negatively with the tumor mass (Supplementary Figure [5C](#SM1){ref-type="supplementary-material"}), suggesting that also some of the hepatic UPR indicators may be associated with the severity of cachexia.

As a third biological process that is connected to redox balance ([@B30]) and UPR ([@B60]) and which contributes to the muscle protein homeostasis, we investigated the indicators of the autophagy-lysosome pathway that is responsible for the degradation and recycling of unnecessary and/or damaged proteins and organelles ([@B52]) from the tumor-bearing mice. We observed increased content of lipidated LC3, increased ratio of LC3II and LC3I (LC3II/LC3I), *Lc3b* mRNA and Beclin-1 in the skeletal muscle of C26 tumor-bearing mice, which indicates increased autophagosome content and the induction of autophagy, respectively. These results were accompanied by increased P62 protein and unchanged *P62* mRNA levels, suggesting decreased clearance of autophagosomes ([@B28]). Our results are consistent with the previous studies conducted with experimental animal models and also in cachectic humans ([@B45]; [@B5]; [@B35]), clearly indicating that autophagy is induced in cachectic muscle and that the clearance of the autophagosomes may be inhibited. Even though the continued sACVR2B-Fc treatment previously inhibited the muscle wasting in the tumor-bearing mice ([@B39]) and has decreased markers of autophagy in healthy mice ([@B27]), the novelty of our present study was that the sACVR2B-Fc treatment did not inhibit the increase in autophagy that was observed 11 days after the C26 inoculation. These results suggest that autophagy contributes to the muscle wasting together with the ubiquitin-proteasome system, which was also upregulated in the muscle of the C26 tumor-bearing mice despite the sACVR treatment ([@B39]). In the liver, as in the skeletal muscle, lipidated LC3 content and LC3II/LC3I were increased in C26 tumor-bearing mice but not P62, suggesting increased autophagosome content without impairment in the autophagic flux. Our results suggest that cancer cachexia induces aberration in the hepatic proteostasis, which is compensated by the induction of autophagy and UPR without any evident ER-stress related apoptosis. The induction of autophagy may also be explained by decreased feed intake, a known stimulus for autophagy activation ([@B51], [@B52]).

In conclusion, experimental cancer cachexia decreased the anti-oxidant defense capacity manifested by decreased glutathione content in skeletal muscle. However, sACVR2B-Fc administration increased glutathione in both healthy and cachectic muscle, suggesting that it increases anti-oxidant defense capacity in skeletal muscle. Based on the correlations of the data, we suggest that alterations in the processes contributing to protein homeostasis are associated with the severity of cachexia. The induction of UPR in the liver but not in skeletal muscle indicates that the protein homeostasis is altered in a tissue-specific manner in C26 cancer cachexia.
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